AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.48
-0.19 (-3.35%)
Jul 24, 2026, 1:23 PM EDT - Market open
AbCellera Biologics Employees
AbCellera Biologics had 562 employees as of December 31, 2025. The number of employees decreased by 34 or -5.70% compared to the previous year.
Employees
562
Change (1Y)
-34
Growth (1Y)
-5.70%
Revenue / Employee
$140,940
Profits / Employee
-$256,149
Market Cap
1.67B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 562 | -34 | -5.70% |
| Dec 31, 2024 | 596 | 10 | 1.71% |
| Dec 31, 2023 | 586 | 91 | 18.38% |
| Sep 30, 2023 | 630 | 155 | 32.63% |
| Jun 30, 2023 | 590 | 140 | 31.11% |
| Mar 31, 2023 | 525 | 125 | 31.25% |
| Dec 31, 2022 | 495 | 109 | 28.24% |
| Sep 30, 2022 | 475 | 115 | 31.94% |
| Jun 30, 2022 | 450 | 148 | 49.01% |
| Mar 31, 2022 | 400 | 194 | 94.17% |
| Dec 31, 2021 | 386 | 180 | 87.38% |
| Sep 30, 2021 | 360 | 186 | 106.90% |
| Jun 30, 2021 | 302 | 128 | 73.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Sarepta Therapeutics | 835 |
| Ascentage Pharma Group International | 767 |
| Immunocore Holdings | 524 |
| Maravai LifeSciences Holdings | 416 |
| Zymeworks | 243 |
| Stoke Therapeutics | 170 |
| Bicara Therapeutics | 103 |
ABCL News
- 14 days ago - 3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts - TipRanks
- 16 days ago - AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 - Business Wire
- 17 days ago - AbCellera upgraded to Buy from Hold at Benchmark - TheFly
- 18 days ago - AbCellera apponts Lynn Seely to board of directors - TheFly
- 18 days ago - AbCellera Appoints Dr. Lynn Seely to its Board of Directors - Business Wire
- 5 weeks ago - Jazz Pharma, AbCellera ink antibody deal worth up to $876 million - Reuters
- 5 weeks ago - Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies - Business Wire
- 7 weeks ago - AbCellera appoints Victor Sandor to board of directors - TheFly